Company / Net Income
Taysha Gene Therapies, Inc. Net Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$109.0M
FY2025
5-year range
-$174.5M / -$109.0M
FY2021-FY2025
Trend
+2.3%
vs FY2024
Sector context
#113 of 216
Health Care
What the data says
At -$109M, Taysha Gene Therapies, Inc.'s net income ranks #113 of 216 in the Health Care sector. Net Income has increased for 3 consecutive years, from -$175M in FY2022 to -$109M in FY2025.
Based on SEC 10-K filings.
-$109M in FY2025.
Improved from -$166M to -$109M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#113 of 216 in Health CareTop 52% of 216This company -$109.0M Sector average $454.3M
▼
-124.0% below sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s net income has grown for 3 consecutive years.
- In FY2025, net income increased 2.3% year-over-year.
- Ranks #113 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$109.0M | +2.3% |
| FY2024 | -$111.6M | +32.8% |
| FY2023 | -$166.0M | +4.9% |
| FY2022 | -$174.5M | +0.0% |
| FY2021 | -$174.5M | -190.8% |
| FY2020 | -$60.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026